Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
J. Miller
Observed names:
John P Miller,
John P. Miller,
John Phillip Miller
Institutions:
University of Rochester Medicine,
University of Rochester
Observed institutions:
Garvan Institute of Medical Research,
University of Rochester Medicine,
UNSW Sydney,
Queen Elizabeth Hospital,
University of Rochester
ORCID:
0000-0001-8786-5442
Observed ORCID:
0000-0001-8786-5442
OpenAlex ID:
A5023194705
Prognostic gene expression signature for high-grade serous ovarian cancer
2020
·
J. Millstein
, T. Budden
, et al.
·
Annals of Oncology
·
172
PDF
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
2020
·
Eun Young Kang
, Dane Cheasley
, et al.
·
Modern Pathology
·
49
PDF
MyD88 and TLR4 Expression in Epithelial Ovarian Cancer
2018
·
Matthew S. Block
, Robert A. Vierkant
, et al.
·
Mayo Clinic Proceedings
·
35
PDF
The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer
2024
·
Kyukwang Kim
, Negar Khazan
, et al.
·
PLoS ONE
·
5
IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2
2026
·
John P Miller
, Kyu Kwang Kim
, et al.
·
eLife
IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2
2026
·
John P Miller
, Kyu Kwang Kim
, et al.
·
eLife
PDF
IL1β/IL1R1/IRAK4 Drives Inflammatory Ovarian Cancer Seeding at the inflamed sites and Is Reversed by an IRAK4 inhibitor UR241-2
2026
·
John P. Miller
, Kyu Kwang Kim
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
Effects of a novel proteasome inhibitor, UR238 on the tumor immune microenvironment and growth in epithelial ovarian cancer
2025
·
John Phillip Miller
, Naixin Zhang
, et al.
·
bioRxiv (Cold Spring Harbor Laboratory)
PDF
Show more works
View as search
Works count:
8
Citation count:
261
H-index:
4
I10-index:
3
Year
Topic
Type